DAFNA Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

DAFNA Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-307,070	Closed	-$1.16M	–	79
2025 Q3	$1.16M	Sell	307,070 -163,930	-35%	-$479K	0.29%	58
2025 Q2	$1.17M	Buy	471,000 +331,000	+236%	+$638K	0.32%	54
2025 Q1	$217K	Hold	140,000	–	–	0.06%	81
2024 Q4	$300K	Buy	140,000 +15,000	+12%	+$43K	0.08%	77
2024 Q3	$544K	Buy	+125,000	New	+$680K	0.13%	70
2023 Q1	–	Sell	-97,500	Closed	-$176K	–	74
2022 Q4	$176K	Sell	97,500 -216,100	-69%	-$389K	0.05%	75
2022 Q3	$530K	Hold	313,600	–	–	0.14%	68
2022 Q2	$771K	Hold	313,600	–	–	0.21%	69
2022 Q1	$869K	Buy	313,600 +107,500	+52%	+$392K	0.23%	73
2021 Q4	$1.1M	Buy	+206,100	New	+$1.44M	0.28%	63

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DAFNA Capital Management's BDTX Position: Q4 2025 in Review

DAFNA Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 307,070 shares — an estimated $1.16M sold.

DAFNA Capital Management first reported a position in BDTX in Q4 2021 and held it in 10 quarters. The position peaked at $1.17M in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

DAFNA Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
DAFNA Capital Management sold 307,070 Black Diamond Therapeutics shares in Q4 2025, an estimated $1.16M.
DAFNA Capital Management first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 10 quarters.
DAFNA Capital Management's Black Diamond Therapeutics position peaked at $1.17M in Q2 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.